Search by PDG name  
   

 

RAF1  
    


    
      Official symbol:  RAF1
      Full name:  Raf-1 proto-oncogene, serine/threonine kinase
      Location:  3p25.2
      Also known as:  Raf-1, c-Raf, CRAF
      Entrez ID:  5894
      Ensembl ID:  ENSG00000132155
      Summary:  This gene is the cellular homolog of viral raf gene (v-raf). The encoded protein is a MAP kinase kinase kinase (MAP3K), which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. Once activated, the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2, which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration. Mutations in this gene are associated with Noonan syndrome 5 and LEOPARD syndrome 2. [provided by RefSeq, Jul 2008]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  0.00  
Gscore (Del):  0.36  
 
Recurrently deleted in 2 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  0.02  
 
Recurrently mutated in 1 cancer type(s)
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  15  (Driver)
 
Fusions detected in 10 cancer type(s)
 
 

    
  Overall
    
  Tissue specific
    
   CRISPR: STRONGLY SELECTIVE 
 RNAi: STRONGLY SELECTIVE 
   
   

    
      Functional class:  Kinase (protein kinase)
      JensenLab PubMed score:  1210.80  (Percentile rank: 96.26%)
      PubTator score:  1317.37  (Percentile rank: 97.37%)
      Target development/druggability level:  TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.